Hirofumi Higuchi

Title: Hirofumi Higuchi: Innovator in Humanized Antibodies

Introduction

Hirofumi Higuchi is a prominent inventor based in Kikuchi, Japan, known for his significant contributions to the field of biotechnology. He holds a total of nine patents, showcasing his innovative approach to developing humanized antibodies that have potential applications in medical treatments.

Latest Patents

Among his latest patents is the "Anti-IGF-I receptor humanized antibody." This invention provides a humanized antibody that increases muscle mass through the IGF-I receptor without lowering blood glucose levels. The antibody is characterized by a specific amino acid sequence, including SEQ ID NOs: 1 to 6, which serves as a complementarity determining region (CDR) sequence, and it specifically binds to the extracellular domain of the IGF-I receptor. Another notable patent is the "Anti-transthyretin humanized antibody," which comprises a complementarity determining region of an H chain with the amino acid sequence shown in SEQ ID NOs: 1 to 3, and an L chain with the sequence shown in SEQ ID NOs: 4 to 6. This humanized antibody is designed to specifically bind to transthyretin (TTR) and inhibit its fibrillization, making it suitable for application in the human body.

Career Highlights

Hirofumi Higuchi has worked with notable organizations, including the Juridical Foundation the Chemo-Sero-Therapeutic Research Institute and Astellas Pharma GmbH. His work in these institutions has contributed to advancements in therapeutic antibody development.

Collaborations

Higuchi has collaborated with esteemed colleagues such as Toshihiro Nakashima and Nobuchika Yamamoto, further enhancing the impact of his research and innovations in the field.

Conclusion

Hirofumi Higuchi's work in developing humanized antibodies represents a significant advancement in biotechnology, with the potential to improve medical treatments. His innovative spirit and collaborative efforts continue to drive progress in this vital area of research.